社区
首页
集团介绍
社区
资讯
行情
学堂
TigerGPT
登录
注册
a062914
IP属地:未知
+关注
帖子 · 24
帖子 · 24
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
a062914
a062914
·
2021-07-01
Hahah
非常抱歉,此主贴已删除
看
422
回复
评论
点赞
1
编组 21备份 2
分享
举报
a062914
a062914
·
2021-06-30
$Sesen Bio, Inc.(SESN)$
lol
看
334
回复
评论
点赞
4
编组 21备份 2
分享
举报
a062914
a062914
·
2021-06-23
Hahahahah
Second Sight Medical Products Announces Pricing of Public Offering
LOS ANGELES, June 23, 2021--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Se
Second Sight Medical Products Announces Pricing of Public Offering
看
400
回复
评论
点赞
3
编组 21备份 2
分享
举报
a062914
a062914
·
2021-06-18
Comment
非常抱歉,此主贴已删除
看
426
回复
1
点赞
2
编组 21备份 2
分享
举报
a062914
a062914
·
2021-04-25
Hahah
校招歧视?网曝B站面试官放言:我们团队都是清华北大 你怎么好意思来?
@胖虎哒哒:
来源:三言财经(ID:sycaijing) 该面试官称,因为面试时间被延长,该同学出现不满情绪。由于之前面试过B站没有拿到offer,该同学表示不服气“大厂都给我offer,小厂竟然没有给”,面试官称这些话刺激到了他,进而发生了一些讨论。 三言财经消息,近日有北邮学生爆料称,在B站北邮校招中受到了歧视,该学生指出面试官在校招中炫耀资产、贬低应试者。 爆料列出了面试官的迷惑行为和言论包括但不限于: 1、北邮人眼界太低了,仅限于一个圈,不如我家孩子,五岁不会说中文,只会说英语,可以和白人交流。 2、某 40 余岁中年男性面试官炫耀自己身价过亿在北京有 x 套房,有辆法拉利。 3、 表示自己团队都为清北或者 qs 前 3 学生,你什么都不会,怎么好意思来? 4、表示北邮人太浮躁,眼界太窄,只注重互联网高薪大厂,虽然哔哩哔哩薪酬一般,但可以让你体会到充实工作的感觉。 5、 在面试结束后,面试官们统一拉黑求职者的联系方式如电话微信等,十分具有纪律性。 爆料还指出,深夜哔哩哔哩校招组拨打电话要求涉事同学删除内网论坛帖子。 据了解,此同学今日凌晨在北邮论坛发帖称,已经与B站校招组沟通过,最先的曝光帖也已经删除,不过该同学称在和同学商议后共同向B站提出要求,即在各大平台公开向北邮道歉。 也有疑似当日面试的北邮学生指出,遇到了类似的遭遇。 对此,B站当日校招的面试官发文回应此事。面试官自我介绍称,18年加入B站,现任某工作室负责人,4月23日以技术面试官的身份参加了招聘会。 该面试官称,因为面试时间被延长,该同学出现不满情绪。由于之前面试过B站没有拿到offer,该同学表示不服气“大厂都给我offer,小厂竟然没有给”,面试官称这些话刺激到了他,进而发生了一些讨论。 该面试官指出当时他的主要观点是:你很优秀,但从学业和实习经历上看,不是很专注,目前没有特别适合游戏行业的地方。所以建议多考虑再
校招歧视?网曝B站面试官放言:我们团队都是清华北大 你怎么好意思来?
看
377
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
a062914
a062914
·
2021-04-25
Please reply n like
看
420
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
a062914
a062914
·
2021-03-17
$Bionano Genomics(BNGO)$
:)
看
267
回复
评论
点赞
2
编组 21备份 2
分享
举报
a062914
a062914
·
2021-03-16
$Nano Dimension(NNDM)$
pls
看
738
回复
1
点赞
点赞
编组 21备份 2
分享
举报
a062914
a062914
·
2021-03-13
Post post
看
315
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
a062914
a062914
·
2021-03-10
Hahhhahah
看
1,207
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3574049057637503","uuid":"3574049057637503","gmtCreate":1611024897427,"gmtModify":1613875882067,"name":"a062914","pinyin":"aongwj","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":59,"tweetSize":24,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.04","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.48%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":158906475,"gmtCreate":1625118262497,"gmtModify":1633944577453,"author":{"id":"3574049057637503","authorId":"3574049057637503","name":"a062914","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574049057637503","authorIdStr":"3574049057637503"},"themes":[],"htmlText":"Hahah","listText":"Hahah","text":"Hahah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/158906475","repostId":"1100862435","repostType":4,"isVote":1,"tweetType":1,"viewCount":422,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":153573611,"gmtCreate":1625039334033,"gmtModify":1631886148448,"author":{"id":"3574049057637503","authorId":"3574049057637503","name":"a062914","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574049057637503","authorIdStr":"3574049057637503"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SESN\">$Sesen Bio, Inc.(SESN)$</a>lol","listText":"<a href=\"https://laohu8.com/S/SESN\">$Sesen Bio, Inc.(SESN)$</a>lol","text":"$Sesen Bio, Inc.(SESN)$lol","images":[{"img":"https://static.tigerbbs.com/d837ed760d43a6d84ea5ab69d6efe6db","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/153573611","isVote":1,"tweetType":1,"viewCount":334,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":123135930,"gmtCreate":1624411704420,"gmtModify":1634006519726,"author":{"id":"3574049057637503","authorId":"3574049057637503","name":"a062914","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574049057637503","authorIdStr":"3574049057637503"},"themes":[],"htmlText":"Hahahahah","listText":"Hahahahah","text":"Hahahahah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123135930","repostId":"2145061761","repostType":4,"repost":{"id":"2145061761","kind":"news","pubTimestamp":1624411200,"share":"https://www.laohu8.com/m/news/2145061761?lang=&edition=full","pubTime":"2021-06-23 09:20","market":"us","language":"en","title":"Second Sight Medical Products Announces Pricing of Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2145061761","media":"Business Wire","summary":"LOS ANGELES, June 23, 2021--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (\"Se","content":"<p><b>LOS ANGELES, June 23, 2021</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/EYES\">Second Sight Medical Products</a>, Inc. (NASDAQ: EYES) (\"Second Sight\" or the \"Company\"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,500,000 shares of common stock, solely to cover over-allotments. All of the shares of common stock are being offered by the Company.</p>\n<p>The offering is expected to close on June 25, 2021, subject to satisfaction of customary closing conditions.</p>\n<p>ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.</p>\n<p>The Company intends to use the net proceeds from the offering primarily for development of the Orion device and general corporate purposes.</p>\n<p>The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-256904), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the \"SEC\") on June 8, 2021 and declared effective on June 14, 2021. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been filed with the SEC on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from the offices of ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673 or by email at prospectus@think-equity.com. Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.</p>\n<p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>\n<p><b>About the Orion Visual Cortical Prosthesis System</b></p>\n<p>Leveraging Second Sight’s 20 years of experience in neuromodulation for vision, the Orion Visual Cortical Prosthesis System (Orion) is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. Orion is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the brain’s visual cortex, where it is intended to provide the perception of patterns of light. A six-subject early feasibility study of the Orion is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and the Baylor College of Medicine in Houston. No peer-reviewed data is available yet for the Orion system.</p>\n<p><b>About Second Sight Medical Products, Inc.</b></p>\n<p>Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Company’s headquarters are in Los Angeles, California. More information is available at https://secondsight.com/.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Second Sight Medical Products Announces Pricing of Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSecond Sight Medical Products Announces Pricing of Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 09:20 GMT+8 <a href=https://finance.yahoo.com/news/second-sight-medical-products-announces-005900674.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>LOS ANGELES, June 23, 2021--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (\"Second Sight\" or the \"Company\"), a leading developer of implantable visual prosthetics that are ...</p>\n\n<a href=\"https://finance.yahoo.com/news/second-sight-medical-products-announces-005900674.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/second-sight-medical-products-announces-005900674.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2145061761","content_text":"LOS ANGELES, June 23, 2021--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (\"Second Sight\" or the \"Company\"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,500,000 shares of common stock, solely to cover over-allotments. All of the shares of common stock are being offered by the Company.\nThe offering is expected to close on June 25, 2021, subject to satisfaction of customary closing conditions.\nThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.\nThe Company intends to use the net proceeds from the offering primarily for development of the Orion device and general corporate purposes.\nThe securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-256904), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the \"SEC\") on June 8, 2021 and declared effective on June 14, 2021. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been filed with the SEC on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from the offices of ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673 or by email at prospectus@think-equity.com. Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.\nThis press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\nAbout the Orion Visual Cortical Prosthesis System\nLeveraging Second Sight’s 20 years of experience in neuromodulation for vision, the Orion Visual Cortical Prosthesis System (Orion) is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. Orion is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the brain’s visual cortex, where it is intended to provide the perception of patterns of light. A six-subject early feasibility study of the Orion is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and the Baylor College of Medicine in Houston. No peer-reviewed data is available yet for the Orion system.\nAbout Second Sight Medical Products, Inc.\nSecond Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Company’s headquarters are in Los Angeles, California. More information is available at https://secondsight.com/.","news_type":1},"isVote":1,"tweetType":1,"viewCount":400,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166935815,"gmtCreate":1623987568137,"gmtModify":1634024555978,"author":{"id":"3574049057637503","authorId":"3574049057637503","name":"a062914","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574049057637503","authorIdStr":"3574049057637503"},"themes":[],"htmlText":"Comment ","listText":"Comment ","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/166935815","repostId":"2144574107","repostType":4,"isVote":1,"tweetType":1,"viewCount":426,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":375895701,"gmtCreate":1619321126703,"gmtModify":1634274256171,"author":{"id":"3574049057637503","authorId":"3574049057637503","name":"a062914","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574049057637503","authorIdStr":"3574049057637503"},"themes":[],"htmlText":"Hahah","listText":"Hahah","text":"Hahah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/375895701","repostId":"375176269","repostType":1,"repost":{"id":375176269,"gmtCreate":1619319504147,"gmtModify":1619328600233,"author":{"id":"3510558082622800","authorId":"3510558082622800","name":"胖虎哒哒","avatar":"https://static.tigerbbs.com/75b95d9326c02813b7b87ba8c1eccb5a","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3510558082622800","authorIdStr":"3510558082622800"},"themes":[],"title":"校招歧视?网曝B站面试官放言:我们团队都是清华北大 你怎么好意思来?","htmlText":"来源:三言财经(ID:sycaijing) 该面试官称,因为面试时间被延长,该同学出现不满情绪。由于之前面试过B站没有拿到offer,该同学表示不服气“大厂都给我offer,小厂竟然没有给”,面试官称这些话刺激到了他,进而发生了一些讨论。 三言财经消息,近日有北邮学生爆料称,在B站北邮校招中受到了歧视,该学生指出面试官在校招中炫耀资产、贬低应试者。 爆料列出了面试官的迷惑行为和言论包括但不限于: 1、北邮人眼界太低了,仅限于一个圈,不如我家孩子,五岁不会说中文,只会说英语,可以和白人交流。 2、某 40 余岁中年男性面试官炫耀自己身价过亿在北京有 x 套房,有辆法拉利。 3、 表示自己团队都为清北或者 qs 前 3 学生,你什么都不会,怎么好意思来? 4、表示北邮人太浮躁,眼界太窄,只注重互联网高薪大厂,虽然哔哩哔哩薪酬一般,但可以让你体会到充实工作的感觉。 5、 在面试结束后,面试官们统一拉黑求职者的联系方式如电话微信等,十分具有纪律性。 爆料还指出,深夜哔哩哔哩校招组拨打电话要求涉事同学删除内网论坛帖子。 据了解,此同学今日凌晨在北邮论坛发帖称,已经与B站校招组沟通过,最先的曝光帖也已经删除,不过该同学称在和同学商议后共同向B站提出要求,即在各大平台公开向北邮道歉。 也有疑似当日面试的北邮学生指出,遇到了类似的遭遇。 对此,B站当日校招的面试官发文回应此事。面试官自我介绍称,18年加入B站,现任某工作室负责人,4月23日以技术面试官的身份参加了招聘会。 该面试官称,因为面试时间被延长,该同学出现不满情绪。由于之前面试过B站没有拿到offer,该同学表示不服气“大厂都给我offer,小厂竟然没有给”,面试官称这些话刺激到了他,进而发生了一些讨论。 该面试官指出当时他的主要观点是:你很优秀,但从学业和实习经历上看,不是很专注,目前没有特别适合游戏行业的地方。所以建议多考虑再","listText":"来源:三言财经(ID:sycaijing) 该面试官称,因为面试时间被延长,该同学出现不满情绪。由于之前面试过B站没有拿到offer,该同学表示不服气“大厂都给我offer,小厂竟然没有给”,面试官称这些话刺激到了他,进而发生了一些讨论。 三言财经消息,近日有北邮学生爆料称,在B站北邮校招中受到了歧视,该学生指出面试官在校招中炫耀资产、贬低应试者。 爆料列出了面试官的迷惑行为和言论包括但不限于: 1、北邮人眼界太低了,仅限于一个圈,不如我家孩子,五岁不会说中文,只会说英语,可以和白人交流。 2、某 40 余岁中年男性面试官炫耀自己身价过亿在北京有 x 套房,有辆法拉利。 3、 表示自己团队都为清北或者 qs 前 3 学生,你什么都不会,怎么好意思来? 4、表示北邮人太浮躁,眼界太窄,只注重互联网高薪大厂,虽然哔哩哔哩薪酬一般,但可以让你体会到充实工作的感觉。 5、 在面试结束后,面试官们统一拉黑求职者的联系方式如电话微信等,十分具有纪律性。 爆料还指出,深夜哔哩哔哩校招组拨打电话要求涉事同学删除内网论坛帖子。 据了解,此同学今日凌晨在北邮论坛发帖称,已经与B站校招组沟通过,最先的曝光帖也已经删除,不过该同学称在和同学商议后共同向B站提出要求,即在各大平台公开向北邮道歉。 也有疑似当日面试的北邮学生指出,遇到了类似的遭遇。 对此,B站当日校招的面试官发文回应此事。面试官自我介绍称,18年加入B站,现任某工作室负责人,4月23日以技术面试官的身份参加了招聘会。 该面试官称,因为面试时间被延长,该同学出现不满情绪。由于之前面试过B站没有拿到offer,该同学表示不服气“大厂都给我offer,小厂竟然没有给”,面试官称这些话刺激到了他,进而发生了一些讨论。 该面试官指出当时他的主要观点是:你很优秀,但从学业和实习经历上看,不是很专注,目前没有特别适合游戏行业的地方。所以建议多考虑再","text":"来源:三言财经(ID:sycaijing) 该面试官称,因为面试时间被延长,该同学出现不满情绪。由于之前面试过B站没有拿到offer,该同学表示不服气“大厂都给我offer,小厂竟然没有给”,面试官称这些话刺激到了他,进而发生了一些讨论。 三言财经消息,近日有北邮学生爆料称,在B站北邮校招中受到了歧视,该学生指出面试官在校招中炫耀资产、贬低应试者。 爆料列出了面试官的迷惑行为和言论包括但不限于: 1、北邮人眼界太低了,仅限于一个圈,不如我家孩子,五岁不会说中文,只会说英语,可以和白人交流。 2、某 40 余岁中年男性面试官炫耀自己身价过亿在北京有 x 套房,有辆法拉利。 3、 表示自己团队都为清北或者 qs 前 3 学生,你什么都不会,怎么好意思来? 4、表示北邮人太浮躁,眼界太窄,只注重互联网高薪大厂,虽然哔哩哔哩薪酬一般,但可以让你体会到充实工作的感觉。 5、 在面试结束后,面试官们统一拉黑求职者的联系方式如电话微信等,十分具有纪律性。 爆料还指出,深夜哔哩哔哩校招组拨打电话要求涉事同学删除内网论坛帖子。 据了解,此同学今日凌晨在北邮论坛发帖称,已经与B站校招组沟通过,最先的曝光帖也已经删除,不过该同学称在和同学商议后共同向B站提出要求,即在各大平台公开向北邮道歉。 也有疑似当日面试的北邮学生指出,遇到了类似的遭遇。 对此,B站当日校招的面试官发文回应此事。面试官自我介绍称,18年加入B站,现任某工作室负责人,4月23日以技术面试官的身份参加了招聘会。 该面试官称,因为面试时间被延长,该同学出现不满情绪。由于之前面试过B站没有拿到offer,该同学表示不服气“大厂都给我offer,小厂竟然没有给”,面试官称这些话刺激到了他,进而发生了一些讨论。 该面试官指出当时他的主要观点是:你很优秀,但从学业和实习经历上看,不是很专注,目前没有特别适合游戏行业的地方。所以建议多考虑再","images":[{"img":"https://static.tigerbbs.com/f474de22b591edfda8569c38cf129af9","width":"550","height":"463"},{"img":"https://static.tigerbbs.com/44ca006a58beaf1ea074ab2a860cd336","width":"550","height":"432"},{"img":"https://static.tigerbbs.com/78abc1afb76e9c032c04b4e391ecc74b","width":"550","height":"220"}],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/375176269","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":6,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":377,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":375892480,"gmtCreate":1619321064840,"gmtModify":1634274256895,"author":{"id":"3574049057637503","authorId":"3574049057637503","name":"a062914","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574049057637503","authorIdStr":"3574049057637503"},"themes":[],"htmlText":"Please reply n like ","listText":"Please reply n like ","text":"Please reply n like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/375892480","isVote":1,"tweetType":1,"viewCount":420,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":324339199,"gmtCreate":1615960913811,"gmtModify":1703495564275,"author":{"id":"3574049057637503","authorId":"3574049057637503","name":"a062914","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574049057637503","authorIdStr":"3574049057637503"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>:)","listText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>:)","text":"$Bionano Genomics(BNGO)$:)","images":[{"img":"https://static.tigerbbs.com/ee50f3065843b65a424e11dd546d2789","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/324339199","isVote":1,"tweetType":1,"viewCount":267,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":325827690,"gmtCreate":1615888010410,"gmtModify":1703494497682,"author":{"id":"3574049057637503","authorId":"3574049057637503","name":"a062914","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574049057637503","authorIdStr":"3574049057637503"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NNDM\">$Nano Dimension(NNDM)$</a>pls","listText":"<a href=\"https://laohu8.com/S/NNDM\">$Nano Dimension(NNDM)$</a>pls","text":"$Nano Dimension(NNDM)$pls","images":[{"img":"https://static.tigerbbs.com/30d80457291c82b1945ee96cf5f61b47","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/325827690","isVote":1,"tweetType":1,"viewCount":738,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":326176129,"gmtCreate":1615607454561,"gmtModify":1703491569790,"author":{"id":"3574049057637503","authorId":"3574049057637503","name":"a062914","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574049057637503","authorIdStr":"3574049057637503"},"themes":[],"htmlText":"Post post ","listText":"Post post ","text":"Post post","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/326176129","isVote":1,"tweetType":1,"viewCount":315,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":323617378,"gmtCreate":1615337727194,"gmtModify":1703487509450,"author":{"id":"3574049057637503","authorId":"3574049057637503","name":"a062914","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574049057637503","authorIdStr":"3574049057637503"},"themes":[],"htmlText":"Hahhhahah","listText":"Hahhhahah","text":"Hahhhahah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/323617378","isVote":1,"tweetType":1,"viewCount":1207,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}